Dr. Robert Foldes

 

Robert

 

Dr. Robert Foldes, founder and CEO, leverages considerable experience in the bio/pharma industry including previously serving as President & CEO of Cytochroma Inc. (acquired by OPKO Health, Inc.) and in various scientific and management roles at Allelix Biopharmaceuticals Inc. (acquired by NPS Pharmaceuticals, Inc.). At Cytochroma, Robert helped to raise more than $24 million in financing and succeeded at in-licensing and advancing the company’s lead drug candidate from research to Phase I clinical studies. He also negotiated the expansion of a license and research agreement with a multi-national specialty pharmaceutical company for a second program that also led to a drug that entered clinical development.

At Allelix, Robert negotiated strategic alliances, joint ventures, and licensing agreements, and managed research collaborations with academia, as well as biotechnology companies. During the early part of his career, Robert was directly involved with cancer research at the University of Vermont, the Eppley Institute for Research in Cancer and Allied Diseases, the Fox Chase Cancer Center, and the Samuel Lunenfeld Research Institute. Robert received his Honours B.Sc. from the University of Toronto, his Ph.D. in Pharmacology from the University of Nebraska Medical Center, and MBA from York University’s Schulich School of Business.

Dr. Tak-Hang (Bill) Chan

 

Bill

 

Dr. Tak-Hang (Bill) Chan, scientific advisor and collaborator, is Professor Emeritus in the Department of Chemistry at McGill University and Distinguished Visiting Chair Professor of Organic Chemistry in the Department of Applied Biology and Chemical Technology at The Hong Kong Polytechnic University. Prof. Chan has made substantial contributions to chemistry for over 40 years and is the namesake in the chemical literature responsible for “Chan’s diene” and the “Chan Rearrangement”. In 2001, Prof. Chan reported the first enantioselective synthesis of epigallocatechin-3-gallate (EGCG).

He is a world-leader in the chemistry of EGCG and it’s analogs as well as that of other flavonoids. Prof. Chan is an inventor of 10 patent families. He has published over 300 refereed publications, reviews, book chapters, and 4 monographs. In 1982, he received the Merck, Sharpe and Dohme Award from the Chemical Institute of Canada for outstanding contributions to organic chemistry by a scientist under 40 years old. In 1993, Prof. Chan was honoured by the R. U. Lemieux Award of the Canadian Society of Chemistry for outstanding research in organic chemistry. He is a Fellow of the Royal Society of Canada. Prof. Chan received his PhD from Princeton University.

Dr. Q. Ping Dou

 

Dr-Ping Dou

 

Dr. Q. Ping Dou, scientific collaborator, is Professor at the Barbara Ann Karmanos Research Institute of Wayne State University. He has appointments in the School of Medicine’s departments of Oncology, Pharmacology, and Pathology as well as its Cancer Biology Program. Prof. Dou was one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells, and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. His laboratory has shown that some tea polyphenols specifically inhibit the chymotrypsin-like activity of the proteasome.

He is a member of the editorial board of several journals including Current Pharmaceutical Design, Current Drugs, Frontiers in Bioscience, and Oncology Reports. Prof. Dou has 190 peer-reviewed publications and is an inventor of 9 patent families. He received his PhD from Rutgers University.